Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Revenue (2016 - 2026)

Aytu Biopharma has reported Revenue over the past 13 years, most recently at $15.2 million for Q4 2025.

  • Quarterly Revenue fell 6.51% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.6 million through Dec 2025, up 2.0% year-over-year, with the annual reading at $66.4 million for FY2025, 1.84% up from the prior year.
  • Revenue was $15.2 million for Q4 2025 at Aytu Biopharma, up from $13.9 million in the prior quarter.
  • Over five years, Revenue peaked at $30.7 million in Q2 2023 and troughed at $13.9 million in Q3 2025.
  • The 5-year median for Revenue is $18.7 million (2023), against an average of $20.4 million.
  • Year-over-year, Revenue surged 61.96% in 2021 and then plummeted 52.52% in 2024.
  • A 5-year view of Revenue shows it stood at $23.1 million in 2021, then grew by 13.64% to $26.3 million in 2022, then dropped by 28.66% to $18.7 million in 2023, then decreased by 13.48% to $16.2 million in 2024, then decreased by 6.51% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Revenue are $15.2 million (Q4 2025), $13.9 million (Q3 2025), and $15.1 million (Q2 2025).